- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: Low-dose naltrexone extends healthspan and lifespan in C. (Pubmed Central) - May 27, 2024
This effect was mediated through SKN-1 (NRF2 in mammals) signaling, influencing innate immune gene expression and upregulating oxidative stress responses. With LDN's low side effects profile, our findings underscore its potential as a geroprotector, suggesting further exploration for promoting healthy aging in humans is warranted.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Review, Journal: Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy. (Pubmed Central) - Mar 28, 2024
Numerous studies on in vitro and in vivo models provide evidence of LDN's positive impact on inhibiting the OGF-OGFr axis in cancers. LDN's unique mechanism of action on cancer cells, lack of direct cytotoxic effect, and immunomodulating action form the basis for its use as an adjuvant in chemotherapy and immunotherapy of cancerous lesions.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Observational data, Journal: Effective Doses of Low-Dose Naltrexone for Chronic Pain - An Observational Study. (Pubmed Central) - Mar 27, 2024
Hormesis was demonstrated during the determination of the maximally effective dosing, which varied over a wide range, with statistically significant improvement in BPI. The maximally effective dose of low-dose naltrexone for the treatment of chronic pain is idiosyncratic, suggesting the need for 1) dosage titration to establish a maximally effective dose and 2) the possibility of re-introduction of low-dose naltrexone to patients who had failed initial trials on a fixed dose of naltrexone.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Use of Low Dose Naltrexone in a Cohort of Patients with Cryptogenic Small Fiber Neuropathy (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_2011;
Results are confounded by limited sample size along with variable LDN dosing and survey intervals. Nevertheless, follow up studies may be beneficial in establishing the benefit of LDN in SFN using larger sample sizes and assessing for response over a longer interval.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Retrospective data, Journal: Efficacy and Safety of Low Dose Naltrexone for Chronic Pain. (Pubmed Central) - Mar 4, 2024
Seven (23%) reported side effects. LDN was associated with a statistically significant reduction in PEG in adult chronic pain patients, however the clinical significance is unclear as over 75% of patients discontinued LDN due to lack of benefit.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open, Trial completion date, Trial primary completion date: Low-dose Naltrexone for Post-COVID Fatigue Syndrome (clinicaltrials.gov) - Mar 1, 2024
P2, N=160, Recruiting,
Low-dose naltrexone, an opioid antagonist with immune-modulatory effects, has emerged as a potential therapeutic option. Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: Low-Dose Naltrexone: A Possible Option for Fibromyalgia. (Pubmed Central) - Feb 27, 2024
Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024 No abstract available
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: Alcohol use disorder in the perioperative period: a summary and recommendations for anesthesiologists and pain physicians. (Pubmed Central) - Dec 5, 2023
This review highlights key considerations for the anesthesiologist and pain physician in the perioperative management of patients with active AUD (or those in recovery). It discusses the effects of acute and chronic alcohol use on pain perception and thresholds, provides guidance on the perioperative management of naltrexone and low-dose naltrexone, and reviews a multimodal approach to pain management.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Clinical, Journal: Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. (Pubmed Central) - Nov 3, 2023
The use of LDN was associated with a fewer number of symptoms, improved clinical symptoms (fatigue, post-exertional malaise, unrefreshing sleep, and abnormal sleep pattern), and a better functional status. This observation warrants testing in rigorous, randomized, placebo-controlled clinical trials.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Review, Journal: Is Fibromyalgia a Fashionable Diagnosis or a Medical Mystery? (Pubmed Central) - Oct 9, 2023
Fibromyalgia can be a devastating and debilitating condition for patients, and clinicians are challenged with its diagnosis and treatment as well. Further research
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: Is low-dose naltrexone effective in chronic pain management? (Pubmed Central) - Sep 24, 2023
Low-dose naltrexone significantly reduced pain by 32% in inflammatory conditions and 44% in neuropathic conditions (SOR, B; single retrospective cohort study). Doses as low as 5.4 mg were found to reduce pain in 95% of patients with fibromyalgia (SOR, B; single prospective dose-response study).
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: Low-Dose Naltrexone Use in Postural Orthostatic Tachycardia Syndrome: A Case Series. (Pubmed Central) - Sep 14, 2023
Although some patients noted benefit, patient-reported outcome measures show a variable response profile. High-quality randomized controlled trials are needed to determine if the treatment is efficacious and should be used outside of a trial basis.
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Psychobiological Mechanisms Underlying Chronic Pain (clinicaltrials.gov) - Sep 7, 2023
P=N/A, N=48, Completed,
High-quality randomized controlled trials are needed to determine if the treatment is efficacious and should be used outside of a trial basis. Recruiting --> Completed | N=100 --> 48 | Trial primary completion date: Mar 2023 --> Jul 2023
- |||||||||| Korsuva IV (difelikefalin IV) / Cara Therap, Maruishi Pharma, libvatrep oral (SAF312) / Novartis, Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: Ocular surface itch and pain: key differences and similarities between the two sensations. (Pubmed Central) - Aug 31, 2023
Identifying contributors to abnormal ocular sensations is vital for precise medical care. Novel therapeutics for these conditions aim to improve patient outcomes and quality of life.
- |||||||||| Toctino (alitretinoin) / Basilea, GSK, Dupixent (dupilumab) / Sanofi, Regeneron, Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Therapeutic dimensions of Hailey-Hailey disease (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3866;
Patience and perseverance are the cornerstones of treatment, different patients may have different outcomes and combining or switching therapy is often necessary. In our cases, systemic alitretinoin, apremilast, and C02 laser dermabrasion effectively controlled relapses.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: The Utilization of Low Dose Naltrexone for Chronic Pain. (Pubmed Central) - Aug 21, 2023
A number of studies have shown the benefits of this drug with inflammatory bowel disease, fibromyalgia, multiple sclerosis, diabetic neuropathy, and complex regional pain syndrome, among others. More studies are needed to approve this medication for specific chronic pain conditions.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial suspension, Trial primary completion date: The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging (clinicaltrials.gov) - Jul 31, 2023
P=N/A, N=2500, Suspended,
More studies are needed to approve this medication for specific chronic pain conditions. Trial completion date: Mar 2023 --> Dec 2023 | Recruiting --> Suspended | Trial primary completion date: Mar 2023 --> Dec 2023
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Low Dose Naltrexone for Improving Function in Pediatric Patients (Hall D-10) - Jul 20, 2023 - Abstract #ASA2023ASA_1199;
Furthermore, the median time to see improvement in pain and/or functionality was 3 months. Physicians with patients on LDN should encourage patients to continue taking the medication for at least 2 months before determining if they are a non-responder to LDN.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series. (Pubmed Central) - Jun 20, 2023
The diagnosis of spondylosis was more often associated with a lack of response to LDN than any other diagnosis. Patients may need to have a trial of several weeks before analgesic effects are seen with LDN.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Review, Journal: Low Dose Naltrexone's Utility for Non-Cancer Centralized Pain Conditions - A Scoping Review. (Pubmed Central) - Jun 11, 2023
Upon review of the current available published studies, it is apparent that further high-quality, well-powered RCTs need to be conducted in order to establish efficacy, standardization for dosing, and determine response times. In summary, LDN continues to offer promising results in the management of pain and other distressing symptoms in patients with chronic centralized pain conditions.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Review, Journal: Low-Dose Naltrexone in Rheumatological Diseases. (Pubmed Central) - May 24, 2023
This review shows that LDN is a promising and safe therapy to be used in some rheumatic disease. However, the data is limited and needs to be reproduced in larger studies.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open: Low Dose Naltrexone for Pain in Patients With HIV (clinicaltrials.gov) - May 3, 2023
P4, N=60, Recruiting,
In the second experiment, we injected LDN (1 Not yet recruiting --> Recruiting
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion, Enrollment change, Trial completion date: IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone (clinicaltrials.gov) - Apr 28, 2023
P4, N=2, Completed,
Not yet recruiting --> Recruiting Recruiting --> Completed | N=44 --> 2 | Trial completion date: Jun 2023 --> Feb 2023
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: Low-dose naltrexone (LDN): consumption trend in Brazilian capitals and the Federal District, 2014-2020 (Pubmed Central) - Mar 13, 2023
Increasing dispensation of LDN was observed in 55.6% of the capitals, being stationary in 44.4%, with no decreasing coefficients. Despite the limited evidence regarding LDN pharmacotherapy and its off-label prescription, the data show that prescription, dispensing, and consumption have been on the increase in Brazil, with emphasis on the central-south regions of the country.
|
